Andrew Daniels, PhD
About
Biography
Andrew (Drew) Daniels is an MD/PhD student at Yale School of Medicine. Prior to attending medical school Drew graduated from The Johns Hopkins University with a BA in Neuroscience. There, he completed research in both immunology, studying the systemic immunosuppression associated with brain tumors; and neuroscience, studying the neural circuitry underlying higher order visual processing using advanced imaging techniques.
During medical school Dr. Daniels built on his passion for immunology and immuno-oncology and earned his PhD under the co-mentorship of Dr. Marcus Bosenberg and Dr. Akiko Iwasaki. His thesis research focused on anti-tumor immunologic memory responses. He investigated critical T cell subsets for memory responses, transcriptional and epigenetic changes that defined these cells, therapeutic strategies to enhance this population, and adoptive cell therapy as a potential treatment modality.
Dr. Daniels maintains a broad interest in tumor immunology and strategies to enhance long-term anti-tumor responses. His clinical interest include head and neck cancers, immunotherapies in these settings, and adoptive cell therapies, and he is applying to otolaryngology residency programs this year.
Education & Training
- PhD
- Yale School of Medicine, Immunobiology (2023)
- BA
- Johns Hopkins University, Neuroscience (2014)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Goran Micevic, MD, PhD
Akiko Iwasaki, PhD
Haris Mirza, MD, PhD
Harriet Kluger, MD
Julie F. Cheung
Koonam Park
Publications
New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events
Micevic G, Daniels A, Flavell R. New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events. British Journal Of Dermatology 2023, 189: 355-357. PMID: 37471669, PMCID: PMC10503525, DOI: 10.1093/bjd/ljad236.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCutaneous immune-related adverse eventsImmune-related adverse eventsSelf-reactive T cellsCheckpoint receptor PD-1PD-1 inhibitorsHalf of patientsImmune checkpoint blockadeAntitumor immune responseReceptor PD-1Adverse eventsCheckpoint blockadePD-1Immune toleranceCTLA-4T cellsImmune responseLandmark studiesMolecular mechanismsFunctional roleCritical functional rolePatientsBlockadeDermatologistsImportant cluesIL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory
Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIL-7R expressionT cellsIL-7RAntitumor memorySuperior antitumor efficacyCell-based therapiesTumor-specific T cellsAntigen-specific T cellsAntitumor efficacyPowerful antitumor immune responseMarkers of exhaustionTumor-specific CD8Antitumor immune responseIndependent prognostic factorAntitumor immune memoryMemory T cellsMajor risk factorSuperior antitumor activityFunctional CD8Memory CD8Prognostic factorsSurgical resectionAdvanced melanomaLymph nodesNaive mice
Academic Achievements and Community Involvement
honor Research Excellence Award in Translational Research
Yale School of Medicine AwardYale Cancer CenterDetails06/30/2023
Links & Media
News
- January 12, 2021
Holiday Telethon and Raffle